Skip to main content

Clinical Trial Search Results

A scientist pointing to an image of a DNA chain.

Clinical Trial Search Results

Showing 55-63 out of 311 results.
NCT05206773

A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults with Fabry Disease who are Treatment-naïve or Untreated for
At least 6 Months

Icon for trial | EFC17045 A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults with Fabry Disease who are Treatment-naïve or Untreated for
At least 6 Mo

This study is currently enrolling.

The purpose of the study is to evaluate daily oral doses of the study drug called venglustat compared to placebo: what is the effectiveness (how well it works) on symptoms of the Fabry disease, mainly neuropathic pain and abdom ...

NCT04161885

A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)

Icon for trial | M19-063 A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)

This study is currently enrolling.

The purpose of this study is to evaluate the safety and efficacy of study drugs venetoclax and azacitidine compared to Best Supportive Care (no study medication) when given as maintenance therapy after allogeneic stem cell tran ...

NCT05382299

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan
Versus Treatment of Physician’s Choice in Patients With Previously
Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative
Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients
Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose
Tumors Do Express PD-L1

Icon for trial | GS-US-592-6238 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan 
Versus Treatment of Physician’s Choice in Patients With Previously 
Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative 
Breast Cancer Whose Tumors Do

This study is currently enrolling.

This study will be recruiting patients with previously untreated, locally advanced, inoperable or metastatic Triple-Negative Breast Cancer whose tumors do not express PD-L1 or patients previously treated with Anti PD-(L)1 Agent ...

NCT05382286

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and
Pembrolizumab Versus Treatment of Physician’s Choice and
Pembrolizumab in Patients With Previously Untreated, Locally Advanced,
Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors
Express PD-L1.

Icon for trial | GS-US-592-6173 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and 
Pembrolizumab Versus Treatment of Physician’s Choice and 
Pembrolizumab in Patients With Previously Untreated, Locally Advanced, 
Inoperable, or Metastatic Triple-N

This study is currently enrolling.

The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve lifespans of patients with advanced, PD-L1 positive TNBC and their tumor does not grow or spread when compared to chemot ...

NCT05507216

ABTECT-2: A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis

Icon for trial | ABTECT-2: A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis

This study is currently enrolling.

Study Purpose: This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of investigational ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to seve ...

NCT04717414

ACE-536-MF-002: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Icon for trial | ACE-536-MF-002 ACE-536-MF-002: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy

This study is currently enrolling.

The main purpose of this study is to see if people with MPN-associated myelofibrosis that need blood transfusions will stop needing RBC transfusions or require less frequent RBC transfusions by taking luspatercept. The safety ...